Stimcell Energetics Posts $90,566 Net Loss in Q3 as R&D Spending Surges 7,316%

Stimcell Energetics Inc., a clinical-stage research company, reported a net loss of $90,566 for the three months ended February 28, 2026, a 35.6% improvement from the $140,537 loss posted in the same quarter of the prior year. The company reported no revenue for either period. Read more earnings reports.

Total operating expenses for the quarter dropped 45.1% to $71,908 from $131,086 a year earlier. The decline was driven by a favorable foreign exchange swing that reduced expenses by $30,146 in the current quarter, compared to a $41,552 charge in the prior-year period. General and administrative expenses fell 75.0% to $8,208 from $32,847.

Research and development costs, however, surged 7,316% to $36,561 from $493 in the year-ago quarter. Management fees held steady at $22,500, while consulting fees edged up 3.2% to $34,785.

Interest expenses climbed 97.4% to $18,658 from $9,451, adding to the quarterly loss.

For the nine months ended February 28, 2026, Stimcell Energetics reported a net loss of $665,916, up 91.9% from $346,964 in the comparable nine-month period of 2025. Operating expenses for the nine-month period rose 92.1% to $617,308 from $321,420, driven by a 332.5% jump in general and administrative expenses to $311,290 and a 29,292.5% surge in research and development costs to $144,905.

The company's balance sheet showed total assets of $34,521 as of February 28, 2026, up from $21,222 at May 31, 2025. Cash on hand stood at $10,257, down from $14,581 at the fiscal year-end. Total liabilities climbed to $1,712,941 from $1,267,508, expanding the working capital deficit to $1,678,420 from $1,246,286.

Notes and advances due to related parties increased to $779,992 from $469,874, while amounts due to related parties rose to $605,231 from $448,536. The company issued 750,000 shares during the nine-month period for services valued at $250,000, bringing total shares outstanding to 20,891,272.

Cash used in operating activities for the nine months totaled $268,570, compared to $83,152 in the prior-year period. Financing activities generated $264,248 in cash, primarily from proceeds from notes due to related parties, compared to $46,745 a year earlier.

Loss per share for the three months ended February 28, 2026, was $0.00 on a basic and diluted basis, unchanged from the prior-year quarter's $0.01 loss despite the lower absolute loss figure. For the nine-month period, loss per share was $0.03 compared to $0.02 in the prior year.